StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) stock

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.08−0.00 (-3.04%)

Close on Nov 17, 2026Market cap $1.60MP/E –Yield –

Vivos Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Vivos Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2023 was $300.00K, down 25.0% year over year. For fiscal 2025 it was $100.00K, up 0.0% from the year before. The highest annual figure on record is $200.00K in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$100.00K0.0%
FY2024Dec 31, 2024$100.00K0.0%
FY2023Dec 31, 2023$100.00K-50.0%
FY2022Dec 31, 2022$200.00K0.0%
FY2021Dec 31, 2021$200.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2024Mar 31, 2024$100.00K–
Q3 FY2023Sep 30, 2023$100.00K0.0%
Q2 FY2023Jun 30, 2023$100.00K0.0%
Q1 FY2023Mar 31, 2023$100.00K0.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$100.00K0.0%
Q2 FY2022Jun 30, 2022$100.00K0.0%
Q1 FY2022Mar 31, 2022$100.00K0.0%
Q4 FY2021Dec 31, 2021$100.00K–
Q3 FY2021Sep 30, 2021$100.00K–
Q2 FY2021Jun 30, 2021$100.00K–
Q1 FY2021Mar 31, 2021$100.00K–

More Vivos Therapeutics figures

See a number that looks wrong?